Authors
Latest:
Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia VeraGhaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.
Latest:
ASCO Congratulates 2024 Special Awards RecipientsASCO and Conquer Cancer will honor individuals who have significantly impacted global cancer care across various domains at the 2024 ASCO Annual Meeting.
Latest:
Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)Grace Dy, MD, presents data from the CARMEN-LC04 study evaluating safety and anti-tumor activity of tusamitamab ravtansine combined with ramucirumab in high CEACAM5-expressing non-squamous cell (NSQ) NSCLC tumors.
Latest:
Memorial Sloan Kettering Cancer Center Launches MSKCC India to Expand Access to World-Renowned Oncologists, Cancer Care, Research, and EducationMemorial Sloan Kettering Cancer Center, the world’s oldest and largest private cancer center, has launched MSKCC India to provide cancer patients in India with access to the institution’s world-renowned oncologists, research, clinical trials, and education.
Latest:
New Cancer Study Results Confirm Lasting Effects on 9/11 First RespondersResearch investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.
Latest:
Dr. Lees on the Utility of Genetic Testing in Ovarian CancerBrittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.
Latest:
Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer TreatmentPratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.
Latest:
Schmid Summarizes Updates in HER2-Positive Breast Cancer ManagementDr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.
Latest:
Dr Torres on Treatment With ADCs in Breast CancerMylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.
Latest:
Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue SarcomaAlessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.
Latest:
Novel Tubulin-Targeting Therapies Make HeadwayClinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.
Latest:
Dr. Hoskins on the Impact of Race on Breast Cancer OutcomesKent Hoskins, MD, discusses the impact of race on breast cancer outcomes.
Latest:
Dr. Ayers on the Evolving Treatment Landscape in CLLEmily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.
Latest:
Dr Dondossola on the Importance of Studying Bone Metastasis in RCCEleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.
Latest:
Dr Grieb on the Need for Novel Biomarkers in CRCBrian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.
Latest:
Narsoplimab Trial ResultsThe panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.
Latest:
Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder TumorsJohn P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.
Latest:
Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in CancerAatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.
Latest:
Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic CancerLacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.
Latest:
Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood CancerMatthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.
Latest:
Dr Santos Castillero on Unmet Needs to Be Addressed in NSCLCEdgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.
Latest:
Dr. Lee on the Association of MSI-H, dMMR, and TMB-H Features in Endometrial CancerSarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.
Latest:
Dr Mikhael on Unmet Needs to Be Addressed in Multiple MyelomaJoseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.
Latest:
Dr Corvigno on Chemotherapy-Related Clonal Hematopoiesis in Ovarian CancerSara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.
Latest:
Dr Wagner or the Potential Value of Immunotherapy in AngiosarcomaMichael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.
Latest:
Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCLCarmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Latest:
Dr. Gradishar on the Significance of Drug Development in HER2+ Breast CancerWilliam Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.
Latest:
Dr. Coston on the Investigation of Bone Metastases in Neuroendocrine NeoplasmsTucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.
Latest:
Dr. Collins on the Rationale for CDK4/6 Inhibitors in ER+ Breast CancerJulie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.
